FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282959897> ?p ?o ?g. }

• W4282959897 endingPage "3400" @default.
• W4282959897 startingPage "3400" @default.
• W4282959897 abstract "Abstract Introduction: Detection of ctDNA in plasma samples permits temporal assessment of tumor mutation status during treatment. Poziotinib is an oral pan-HER TKI that has been demonstrated to be efficacious in NSCLC patients harboring HER2 exon 20 insertion mutations. We assessed serial plasma samples for changes in tumor genotype in both treatment naive and second line patients to evaluate correlation with clinical response. Methods: For NSCLC patients, HER2 exon 20 insertion mutations identified by tumor tissue based NGS were required for entry into the ZENITH20 study. Plasma samples were collected prior to treatment and at C3D1 (8 weeks post treatment 16mg poziotinib QD). The Guardant360® 74-gene liquid biopsy assay, which assessed changes in ctDNA and, subsequently, mean variant allele fraction (mVAF), was utilized for analysis of samples. The Guardant360 Response™ Molecular Response (MR) algorithm was calculated as a ratio of mVAF of oncogenic alterations at baseline compared to poziotinib treatment at C3D1. Results: 23 patients with tumor tissue confirmed NSCLC harboring HER2 exon 20 insertion mutations were studied. 22 of 23 (96%) had baseline plasma samples with detectable ctDNA. 21 of 22 samples had detectable HER2 exon 20 insertion mutations, resulting in a concordance of 95% versus tissue based NGS. The most prevalent HER2 exon 20 insertion alteration was the A775_G776ins YVMA variant, found in 50% of the baseline blood and tumor samples using both methods (100% concordance). 16 of 17 patients had both baseline and C3D1 samples, permitting assessment of temporal response. 15 of the 16 (94%) patients demonstrated a decrease in mVAF at C3D1 compared to the mVAF at baseline. 12 of 15 patients demonstrated an &gt;50% reduction in mVAF at C3D1, with 7 of the 12 patients showing &gt;95% reduction in mVAF at C3D1 with clinical outcomes of 5 PRs, 1 non-CR/non-PD and 1 SD. Interestingly, 3 of these patients showed complete clearance of ctDNA target HER2 exon 20 insertions at the C3D1 timepoint. Conclusions: Baseline plasma ctDNA genotyping correlated with tumor tissue based NGS in an NSCLC patient population with HER2 mutations. Poziotinib treatment resulted in mVAF reduction, which correlated with clinical response per RECIST1.1. Assessment of longitudinal changes in ctDNA during drug therapy may potentially be used to predict patient response and possibly tumor resistance. Further evaluation in larger cohorts and longer duration of treatment is required to help elucidate the impact of these findings. Citation Format: Arunthi Thiagalingam, Sribalaji Lakshmikanthan, Allysia J. Mak, Scott A. Shell, Sharon Leu, Rocky Washington, Lyndah Dreiling, Gajanan Bhat, Francois Lebel, John A. Barrett. Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3400." @default.
• W4282959897 created "2022-06-17" @default.
• W4282959897 creator A5006736035 @default.
• W4282959897 creator A5009640259 @default.
• W4282959897 creator A5010229789 @default.
• W4282959897 creator A5039215755 @default.
• W4282959897 creator A5054793665 @default.
• W4282959897 creator A5060936292 @default.
• W4282959897 creator A5064985805 @default.
• W4282959897 creator A5072401254 @default.
• W4282959897 creator A5083337698 @default.
• W4282959897 creator A5091668678 @default.
• W4282959897 date "2022-06-15" @default.
• W4282959897 modified "2023-09-26" @default.
• W4282959897 title "Abstract 3400: Predictive ability of circulating tumor DNA by Guardant360 in poziotinib-treated patients with NSCLC harboring HER2 exon 20 insertion mutations" @default.
• W4282959897 doi "https://doi.org/10.1158/1538-7445.am2022-3400" @default.
• W4282959897 hasPublicationYear "2022" @default.
• W4282959897 type Work @default.
• W4282959897 citedByCount "0" @default.
• W4282959897 crossrefType "journal-article" @default.
• W4282959897 hasAuthorship W4282959897A5006736035 @default.
• W4282959897 hasAuthorship W4282959897A5009640259 @default.
• W4282959897 hasAuthorship W4282959897A5010229789 @default.
• W4282959897 hasAuthorship W4282959897A5039215755 @default.
• W4282959897 hasAuthorship W4282959897A5054793665 @default.
• W4282959897 hasAuthorship W4282959897A5060936292 @default.
• W4282959897 hasAuthorship W4282959897A5064985805 @default.
• W4282959897 hasAuthorship W4282959897A5072401254 @default.
• W4282959897 hasAuthorship W4282959897A5083337698 @default.
• W4282959897 hasAuthorship W4282959897A5091668678 @default.
• W4282959897 hasConcept C104317684 @default.
• W4282959897 hasConcept C118083812 @default.
• W4282959897 hasConcept C121608353 @default.
• W4282959897 hasConcept C126322002 @default.
• W4282959897 hasConcept C135763542 @default.
• W4282959897 hasConcept C142724271 @default.
• W4282959897 hasConcept C143998085 @default.
• W4282959897 hasConcept C153911025 @default.
• W4282959897 hasConcept C160798450 @default.
• W4282959897 hasConcept C2775934546 @default.
• W4282959897 hasConcept C2779529041 @default.
• W4282959897 hasConcept C36823959 @default.
• W4282959897 hasConcept C501734568 @default.
• W4282959897 hasConcept C502942594 @default.
• W4282959897 hasConcept C54355233 @default.
• W4282959897 hasConcept C71924100 @default.
• W4282959897 hasConcept C86803240 @default.
• W4282959897 hasConceptScore W4282959897C104317684 @default.
• W4282959897 hasConceptScore W4282959897C118083812 @default.
• W4282959897 hasConceptScore W4282959897C121608353 @default.
• W4282959897 hasConceptScore W4282959897C126322002 @default.
• W4282959897 hasConceptScore W4282959897C135763542 @default.
• W4282959897 hasConceptScore W4282959897C142724271 @default.
• W4282959897 hasConceptScore W4282959897C143998085 @default.
• W4282959897 hasConceptScore W4282959897C153911025 @default.
• W4282959897 hasConceptScore W4282959897C160798450 @default.
• W4282959897 hasConceptScore W4282959897C2775934546 @default.
• W4282959897 hasConceptScore W4282959897C2779529041 @default.
• W4282959897 hasConceptScore W4282959897C36823959 @default.
• W4282959897 hasConceptScore W4282959897C501734568 @default.
• W4282959897 hasConceptScore W4282959897C502942594 @default.
• W4282959897 hasConceptScore W4282959897C54355233 @default.
• W4282959897 hasConceptScore W4282959897C71924100 @default.
• W4282959897 hasConceptScore W4282959897C86803240 @default.
• W4282959897 hasIssue "12_Supplement" @default.
• W4282959897 hasLocation W42829598971 @default.
• W4282959897 hasOpenAccess W4282959897 @default.
• W4282959897 hasPrimaryLocation W42829598971 @default.
• W4282959897 hasRelatedWork W2520919442 @default.
• W4282959897 hasRelatedWork W2761902301 @default.
• W4282959897 hasRelatedWork W2767675663 @default.
• W4282959897 hasRelatedWork W2893982277 @default.
• W4282959897 hasRelatedWork W3042631101 @default.
• W4282959897 hasRelatedWork W3177012050 @default.
• W4282959897 hasRelatedWork W4282959897 @default.
• W4282959897 hasRelatedWork W4282983770 @default.
• W4282959897 hasRelatedWork W4310490811 @default.
• W4282959897 hasRelatedWork W4379284398 @default.
• W4282959897 hasVolume "82" @default.
• W4282959897 isParatext "false" @default.
• W4282959897 isRetracted "false" @default.
• W4282959897 workType "article" @default.